RRM1 and small intestine cancer: RRM1 positivity (negativity has been related to gemcitabine response34) was associated with TMB‐H status in eight tumor types: small intestinal cancer (p = 0.005), pancreatic cancer (p = 0.004), cancer with unknown primary (p = 0.010), nonsmall cell lung cancer (p = 0.012), female genital tract malignancy (p < 0.001), epithelial ovarian cancer (p < 0.001), breast cancer (p = 0.040) and bladder cancer (p = 0.019).